Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study

Jinxing Lou(Shanghai University), Qijun Qian(Shanghai University), Xinhong Guan(Shanghai University), Lijie Rong(Shanghai Cell Therapy Research Institute), Hongfan Zhu(Shanghai Cancer Institute), Zhi‐Feng Miao(Kaohsiung Medical University), Shuya Wang(Central South University), Wenfeng Xu(Vyne Therapeutics (United States)), Yi Liu(China National Building Materials Group (China)), Zhicai Lin(Shanghai Cell Therapy Research Institute), Yan Gao(North China University of Science and Technology), Mengxin Xia(Shanghai University of Traditional Chinese Medicine), F. C. Ma(Shanghai Cell Therapy Research Institute), Yan Sun(Tianjin Medical University General Hospital)
Blood
November 3, 2025
Cited by 0


Related Papers